Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Grippol Quadrivalent Vaccine in Children
NCT06385821Phase 3Completed
- Sponsor
- Petrovax Pharm
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Grippol Quadrivalent in influenza (2 arms), sponsored by Petrovax Pharm. Primary endpoint: Proportion of vaccinated with seroconversion in paired sera of the hemagglutination inhibition reaction. Started Sep 2022; status: completed.
02
Drugs
Grippol Quadrivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06385821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06385821.